Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., . . . Kagamu, H. (2019). Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Wiley.
Chicago Style citaatYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
MLA citatieYamaguchi, Ou, et al. Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab. Wiley, 2019.
Let op: Deze citaties zijn niet altijd 100% accuraat.